Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05898776

10°C vs 4°C Lung Preservation RCT

Despite lung transplantation (LTx) being the most effective treatment for end-stage lung disease, its success rate is lower than that of other solid organ transplantations. Primary graft dysfunction (PGD) is the most common post-operative complication and a major factor in early mortality and morbidity, affecting ~25% of lung transplant patients. Induced by ischemia reperfusion, PGD represents a severe and acute lung injury that occurs within the first 72 hours after transplantation, and has a significant impact on short- and long-term outcomes, and a significant increase in treatment costs. Any intervention that reduces the risk of PGD will lead to major improvements in short- and long-term transplant outcomes and health care systems.

One of the main strategies to reduce the risk and severity of post-transplant PGD is to improve pre-transplant donor lung preservation methods. In current practice, lung preservation is typically performed by cold flushing the organ with a specialized preservation solution, followed by subsequent hypothermic storage on ice (~4°C). This method continues to be used and applied across different organ systems due to its simplicity and low cost. Using this method for the preservation of donor lungs, the current maximum accepted preservation times have been limited to approximately 6-8h. While the goal of hypothermic storage is to sustain cellular viability during ischemic time through reduced cellular metabolism, lower organ temperature has also been shown to progressively favor mitochondrial dysfunction. Therefore, the ideal temperature for donor organ preservation remains to be defined and should maintain a balance between avoidance of mitochondrial dysfunction and prevention of cellular exhaustion. In addition to that, safe and longer preservation times can lead to multiple advantages such as moving overnight transplants to daytime, more flexibility to transplant logistics, more time for proper donor to recipient matching etc.

Building on pre-clinical research suggesting that 10°C may be the optimal lung storage temperature, a prospective, multi-center, non-randomized clinical trial was conducted at University Health Network, Medical University of Vienna and Puerta de Hierro Majadahonda University Hospital. Donor lungs meeting criteria for direct transplantation and with cross clamp times between 6:00pm - 4:00am were intentionally delayed to an earliest allowed start time of 6:00am and a maximum preservation time from donor cold flush to recipient anesthesia start time of 12 hours. Lungs were retrieved and transported in the usual fashion using a cooler with ice and transferred to a 10°C temperature-controlled cooler upon arrival to transplant hospital until implantation. The primary outcome of this study was incidence of Primary Graft Dysfunction (PGD) Grade 3 at 72h, with secondary endpoints including: recipient time on the ventilator, ICU Length of Stay (LOS), hospital LOS, 30-day survival and lung function at 1-year. Outcomes were compared to a contemporaneous conventionally transplanted recipient cohort using propensity score matching at a 1:2 ratio. 70 patients were included in the study arm. Post-transplant outcomes were comparable between the two groups for up to 1 year. Thus, intentional prolongation of donor lung preservation at 10°C was shown to be clinically safe and feasible.

In the current study design, the investigators will conduct a multi-centre, non-inferiority, randomized, controlled trial of 300 participants to compare donor lung preservation from the time of explant to implant at ~10°C in X°Port Lung Transport Device (Traferox Technologies Inc.) vs a standard ice cooler. When eligible donor lungs become available for a consented recipient, the lungs will be randomized to undergo a preservation protocol using either 10°C (X°Port Lung Transport Device, Traferox Technologies Inc.) or standard of care. The primary outcome of the study is incidence of ISHLT Primary Graft Dysfunction Grade 3 at 72 hours. Post-transplant outcomes will be followed for one year.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

St Vincent's Hospital Sydney Limited, Sydney, New South Wales, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Donor Inclusion Criteria

  • Donation after brain death (DBD) or donation after cardiac death (DCD)
  • Donor lungs are suitable to go straight to LTx (i.e., do not need ex vivo lung perfusion (EVLP) assessment)

Donor Exclusion Criteria

  • Concerns with organ preservation technique
  • Need for EVLP assessment

Recipient Inclusion Criteria

  • 18-80 years old
  • Primary lung transplantation
  • Bilateral lung transplantation

Recipient Exclusion Criteria

  • Re-transplantation
  • Multi-organ transplantation
  • Single lung transplantation
  • Participation in a contraindicating trial

Treatment and study plan

Lung transplantation after 10°C donor lung preservation

Device

When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to 10°C preservation will be stored, transported and preserved in the X°Port Lung Transport Device (Traferox Technologies Inc.) until implant with a maximum time of 12 hours between the donor and recipient surgeries.

Lung transplantation after standard ice cooler donor lung preservation

Device

When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to standard preservation will be will be stored, transported and preserved in an ice cooler (~4°C, standard of care) until implant with a maximum time of 6 hours between the donor and recipient surgeries.

Primary outcomes

  1. Incidence of Primary Graft Dysfunction (PGD) Grade 3 as per International Society for Heart and Lung Transplantation (ISHLT)

    Time frame: 72 hours post-transplant

    PGD is graded on a scale of 0 to 3 based on ISHLT guidelines, where PGD Grade 3 indicates severe primary graft dysfunction.

Secondary outcomes

  1. Incidence of Primary Graft Dysfunction Grade 2-3 as per International Society for Heart and Lung Transplantation

    Time frame: 0 (ICU arrival), 24, 48, and 72 hours post-transplant

    PGD is graded on a scale of 0 to 3 based on ISHLT guidelines, where PGD Grade 3 indicates severe primary graft dysfunction.

  2. Time on ventilator

    Time frame: Index hospitalization (up to 1 year)

  3. Total ICU and hospital length of stay

    Time frame: Index hospitalization (up to 1 year)

  4. Overall survival

    Time frame: 30 days, 1 year post-transplant

  5. Occurrence of acute rejection

    Time frame: 1 year post-transplant

  6. Six minute walk test

    Time frame: 1 year post-transplant

  7. Forced expiratory volume - one second (FEV1 in L)

    Time frame: 1 year post-transplant

Sponsors and collaborators

Lead sponsor

University Health Network, Toronto

Other

Collaborators

  • Centre Hospitalier Universitaire Vaudois
  • Centre hospitalier de l'Université de Montréal (CHUM)
  • Corewell Health West
  • Dignity Health
  • Hospital Universitario 12 de Octubre
  • Marie Lannelongue Hospital, Le Plessis Robinson, France
  • Mayo Clinic
  • Medical University of Vienna
  • Puerta de Hierro University Hospital
  • St Vincent's Hospital, Sydney
  • University Hospital of Leuven Leuven
  • University Hospital, Zürich
  • University of California, San Francisco
  • University of Miami
  • University of Texas Southwestern Medical Center
  • Vanderbilt University

Registry information

Official study title

Safety of 10°C Lung Preservation vs. Standard of Care: A Multi-Centre Prospective Non-Inferiority Trial

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Jun 12, 2023
Registry last updated
Mar 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.